MiNK Therapeutics, Inc.
Developing allogeneic iNKT cell therapies for cancer and immune-mediated diseases.
INKT | NDAQ
Overview
Corporate Details
- ISIN(s):
- US6036931029
- LEI:
- Country:
- United States of America
- Address:
- 149 FIFTH AVENUE, 10010 NEW YORK
- Website:
- https://www.minktherapeutics.com
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. The company's platform leverages iNKT cells, which combine the cytotoxicity of natural killer (NK) cells with the memory response of T cells to enhance innate and adaptive immunity. Its lead product candidate, AGENT-797, is an off-the-shelf therapy being evaluated in multiple Phase 1 trials and is designed for administration without lymphodepletion or HLA matching. MiNK is also developing a next-generation technology platform for novel engineered iNKT cell therapies and bispecific iNKT cell engagers.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all MiNK Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for MiNK Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for MiNK Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
